Skip to main content

Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation

Objective

Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ transplantation as the disease progresses. At Opsona Therapeutics we have developed a novel antibody (OPN-305) which has received OMP designation (EU/3/09/638) for use in the prevention of DGF. The scientific basis of this development is the inhibition of Toll-like receptor 2 (TLR2)-mediated ischaemic reperfusion injury which has a pivotal role in the pathogenesis of DGF and its sequelae. The MABSOT project is designed to progress the development of this OMP through Phase I and II clinical trial. The successful completion of the programme will allow the continued development of OPN-305 as an OMP for the treatment of DGF in a range of solid organ transplant situations. OPN-305 development will have significant benefit to these patients and health care providers in reducing the prolonged hospitalisation of these individuals, providing greater longevity associated with the transplanted organ and enhanced quality of life for these individuals.

Call for proposal

FP7-HEALTH-2010-single-stage
See other projects for this call

Coordinator

OPSONA THERAPEUTICS LIMITED
Address
Tara Street Ashford House 2Nd Floor
2 Dublin
Ireland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 232 195
Administrative Contact
Mary Reilly (Ms.)

Participants (9)

KING'S COLLEGE LONDON
United Kingdom
EU contribution
€ 1 051 131
Address
Strand
WC2R 2LS London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Paul Labbett (Mr.)
EURAM LIMITED
United Kingdom
EU contribution
€ 249 187
Address
Lucy Tower Street Tower House
LN1 1XW Lincoln
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Andrew Banasik (Mr.)
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 449 088
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Elke Lammertyn (Dr.)
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Participation ended

Spain
Address
Avenida Gran Via Hospitalet 199-203
08908 L'hospitalet De Llobregat
Activity type
Research Organisations
Administrative Contact
Victoria Cochrane (Ms.)
Institut klinické a experimentální mediciny
Czechia
EU contribution
€ 353 271
Address
Videnska 1958/9
14021 Prague 4
Activity type
Research Organisations
Administrative Contact
Tomas Linhart (Mr.)
UNIVERSITY OF NEWCASTLE UPON TYNE
United Kingdom
EU contribution
€ 427 434
Address
Kings Gate
NE1 7RU Newcastle Upon Tyne
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Aleona Blinova (Ms.)
ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands
EU contribution
€ 443 599
Address
Hanzeplein 1
9713 GZ Groningen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Johanna M Van Apeldoorn (Ms.)
ALMAC DIAGNOSTIC SERVICES LIMITED
United Kingdom
EU contribution
€ 261 511
Address
Seagoe Industrial Estate 20
BT63 5QD Craigavon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Valerie Cooke (Ms.)
INSTITUT CATALA DE LA SALUT
Spain
EU contribution
€ 461 648
Address
Gran Via De Les Corts Catalanes 587
08007 Barcelona
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Laia Lagunas (Ms.)